Entera Bio (ENTX) Change in Account Payables (2021 - 2026)
Entera Bio's (ENTX) quarterly Change in Account Payables came in at -$174000.0 in Q1 2026, down 8800.0% YoY from $2000.0 in Q1 2025, and down 175.0% on a QoQ basis from $232000.0 in Q4 2025.
Entera Bio (ENTX) Change in Account Payables (2021 - 2026) Analysis & Trends
Entera Bio (ENTX) has 6 years of Change in Account Payables data on file, last reported at -$174000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 8800.0% year-over-year to -$174000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140000.0 (up 105.88% YoY) and the FY2025 annual result came in at $316000.0, up 544.9% from the prior year.
- Change in Account Payables fell to -$174000.0 in Q1 2026, from $232000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $324000.0 in Q3 2023 to a low of -$481000.0 in Q4 2023.
- A 5-year average of $6352.9 and a median of $3000.0 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2025 — Change in Account Payables surged 8200.0% — and 2026, when it sank 8800.0%.
- Tracing ENTX's Change in Account Payables over 5 years: stood at -$396000.0 in 2022, then fell by 21.46% to -$481000.0 in 2023, then surged by 89.19% to -$52000.0 in 2024, then jumped by 546.15% to $232000.0 in 2025, then sank by 175.0% to -$174000.0 in 2026.
- The last three Change in Account Payables figures came in at -$174000.0 (Q1 2026), $232000.0 (Q4 2025), and -$167000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 301,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 301,000.00 |
| Jun 30, 2026 | 301,000.00 |
| Mar 31, 2026 | -174,000.00 |
| Mar 31, 2026 | -174,000.00 |
| Dec 31, 2025 | 232,000.00 |
| Dec 31, 2025 | 232,000.00 |
| Sep 30, 2025 | -167,000.00 |
| Sep 30, 2025 | -167,000.00 |
| Jun 30, 2025 | 249,000.00 |
| Jun 30, 2025 | 249,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | -52,000.00 |
| Dec 31, 2024 | -52,000.00 |
| Sep 30, 2024 | 115,000.00 |
| Sep 30, 2024 | 115,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | -17,000.00 |
| Mar 31, 2024 | -17,000.00 |